Profil bibliographique

Dean A. Lee

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

492Publications signalées

14055Citations signalées

1Affiliations récentes

Institutions déclarées

Domaines associés

Immune Cell Function and InteractionCAR-T cell therapy researchT-cell and B-cell ImmunologyHematopoietic Stem Cell TransplantationVirus-based gene therapy research

Publications récentes

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure 5 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22

Sumithira Vasu, Nathan Denlinger, No‐Joon Song, Danielle Elsberry et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Table 3 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22

Sumithira Vasu, Nathan Denlinger, No‐Joon Song, Danielle Elsberry et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Table 1 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22

Sumithira Vasu, Nathan Denlinger, No‐Joon Song, Danielle Elsberry et autres

0 citations

Accès ouvert 2026 otherOpenAlex

Clinical Protocol 1 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22

Sumithira Vasu, Nathan Denlinger, No‐Joon Song, Danielle Elsberry et autres

0 citations

Accès ouvert 2026 otherOpenAlex

Data from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22

Sumithira Vasu, Nathan Denlinger, No‐Joon Song, Danielle Elsberry et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure 1 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22

Sumithira Vasu, Nathan Denlinger, No‐Joon Song, Danielle Elsberry et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure 4 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22

Sumithira Vasu, Nathan Denlinger, No‐Joon Song, Danielle Elsberry et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure 6 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22

Sumithira Vasu, Nathan Denlinger, No‐Joon Song, Danielle Elsberry et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure 2 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22

Sumithira Vasu, Nathan Denlinger, No‐Joon Song, Danielle Elsberry et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure 3 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22

Sumithira Vasu, Nathan Denlinger, No‐Joon Song, Danielle Elsberry et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Table 2 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22

Sumithira Vasu, Nathan Denlinger, No‐Joon Song, Danielle Elsberry et autres

0 citations

Accès ouvert 2026 datasetOpenAlex

Dosage of the fusion transcription factor PAX3::FOXO1 controls cell state in rhabdomyosarcoma

Rachel A. Hoffman, Zhiyu Song, Benjamin Z. Stanton, Dean A. Lee

0 citationsZenodo (CERN European Organization for Nuclear Research)

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.